FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2544941612> ?p ?o ?g. }

• W2544941612 abstract "Abstract Background The treatment combination of traditional Chinese medicine with western medicine results in significant decrease of serum hepatitis B virus (HBV) DNA and increase of HBeAg loss in patients with HBeAg-positive chronic hepatitis B (CHB) without any serious adverse events. We aimed to assess whether the Bushenjianpi Formula combined with entecavir could increase the HBsAg loss rate in patients with HBeAg-negative CHB. Methods In this multicentre, randomised, double-blind, placebo-controlled trial, we recruited patients with HBeAg-negative CHB from ten third-level grade-A hospital of Traditional Chinese Medicine. The inclusion criteria included a history of HBV or HBsAg positive for more than 6 months; positivity for HBsAg or HBV DNA; persistent HBeAg-negativity or HBeAb positivity; HBV DNA concentration of 1 × 10 4 copies per mL or higher by PCR assay at least 4 weeks before screening; alanine aminotransferase (ALT) concentrations of 2 × ULN or greater, or 1 × ULN≤ALT 2 tests and independent-sample t -test to assess differences between groups. This study was conducted in accordance with the ethics principles of the Declaration of Helsinki and approved by the Ethical Committee of Shuguang Hospital, Shanghai University of Traditional Chinese Medicine. All patients were written informed consent. Findings Between Dec 1, 2012, and March 31, 2016, 620 patients with HBeAg-negative CHB were recruited, and they were randomly assigned to the treatment group (320 patients) and the control group (320 patients). After 96 weeks of treatment, the percentage of patients who had reduction in serum HBsAg concentrations decreased more than 1Log10 in the treatment group (11·76%), which was significantly higher than that in control group (6·41%; p=0·043). The rate of HBsAg negative conversion was determined by the ratio between the number of patients whose HBsAg level was lower than 0·1 IU/mL and the total number of patients in every group after treatment. The rate of HBsAg negative conversion was significantly greater in the treatment group (5·13%) than in control group (2·10%; p=0·046). The cccDNA level of liver tissue after treatment was lower than that before treatment in both groups (p=0·001). In this study, there were five cases of adverse events in treatment group and six cases of adverse events in control group. The symptoms in adverse events included cold, fever, and diarrhoea. Interpretation The combination of Bushenjianpi Formula with entecavir could result in a decrease of serum HBsAg and liver tissue cccDNA, as well as increase of HBsAg negative conversion for patients with HBeAg-negative CHB. Funding National Natural Science Foundation of China (81473477, 81403354, 81473629, 81403351, 81503545), Science Research Project of Twelve Five-year Plan (2012ZX10005004–002), Shanghai Rising-Star Program (13QA1403500), the Key Technology Research of Shanghai Municipal Science (13401902900), Three-year action plan of development of TCM in Shanghai (ZYSNXD-CC-ZDYJ015 and ZY3-CCCX-3–3027), Training plan of outstanding young medical talents, Shanghai Municipal Health Bureau (XYQ2013093), Shanghai Sailing Program (14YF1411600, 15YF1412300), Wang Baoen liver fibrosis research fund of China foundation for Hepatitis Prevention and Control (CFHPC20131045, CFHPC20131046) and the Budgeted Projects of Shanghai University of Traditional Chinese Medicine (2013JW40, 2014YSN39)." @default.
• W2544941612 created "2016-11-04" @default.
• W2544941612 creator A5006651636 @default.
• W2544941612 creator A5025832492 @default.
• W2544941612 creator A5037050291 @default.
• W2544941612 creator A5044069774 @default.
• W2544941612 creator A5047258558 @default.
• W2544941612 creator A5053038212 @default.
• W2544941612 creator A5053985637 @default.
• W2544941612 date "2016-10-01" @default.
• W2544941612 modified "2023-09-27" @default.
• W2544941612 title "Bushenjianpi formula combined with entecavir for HBeAg-negative chronic hepatitis B patients: a multicentre, randomised, double-blind, placebo-controlled trial" @default.
• W2544941612 doi "https://doi.org/10.1016/s0140-6736(16)31960-2" @default.
• W2544941612 hasPublicationYear "2016" @default.
• W2544941612 type Work @default.
• W2544941612 sameAs 2544941612 @default.
• W2544941612 citedByCount "1" @default.
• W2544941612 countsByYear W25449416122019 @default.
• W2544941612 crossrefType "journal-article" @default.
• W2544941612 hasAuthorship W2544941612A5006651636 @default.
• W2544941612 hasAuthorship W2544941612A5025832492 @default.
• W2544941612 hasAuthorship W2544941612A5037050291 @default.
• W2544941612 hasAuthorship W2544941612A5044069774 @default.
• W2544941612 hasAuthorship W2544941612A5047258558 @default.
• W2544941612 hasAuthorship W2544941612A5053038212 @default.
• W2544941612 hasAuthorship W2544941612A5053985637 @default.
• W2544941612 hasBestOaLocation W25449416121 @default.
• W2544941612 hasConcept C126322002 @default.
• W2544941612 hasConcept C142724271 @default.
• W2544941612 hasConcept C203014093 @default.
• W2544941612 hasConcept C204787440 @default.
• W2544941612 hasConcept C2522874641 @default.
• W2544941612 hasConcept C27081682 @default.
• W2544941612 hasConcept C2775940106 @default.
• W2544941612 hasConcept C2776175608 @default.
• W2544941612 hasConcept C2777382497 @default.
• W2544941612 hasConcept C2777410769 @default.
• W2544941612 hasConcept C2777869810 @default.
• W2544941612 hasConcept C2780593183 @default.
• W2544941612 hasConcept C71924100 @default.
• W2544941612 hasConcept C90924648 @default.
• W2544941612 hasConceptScore W2544941612C126322002 @default.
• W2544941612 hasConceptScore W2544941612C142724271 @default.
• W2544941612 hasConceptScore W2544941612C203014093 @default.
• W2544941612 hasConceptScore W2544941612C204787440 @default.
• W2544941612 hasConceptScore W2544941612C2522874641 @default.
• W2544941612 hasConceptScore W2544941612C27081682 @default.
• W2544941612 hasConceptScore W2544941612C2775940106 @default.
• W2544941612 hasConceptScore W2544941612C2776175608 @default.
• W2544941612 hasConceptScore W2544941612C2777382497 @default.
• W2544941612 hasConceptScore W2544941612C2777410769 @default.
• W2544941612 hasConceptScore W2544941612C2777869810 @default.
• W2544941612 hasConceptScore W2544941612C2780593183 @default.
• W2544941612 hasConceptScore W2544941612C71924100 @default.
• W2544941612 hasConceptScore W2544941612C90924648 @default.
• W2544941612 hasLocation W25449416121 @default.
• W2544941612 hasOpenAccess W2544941612 @default.
• W2544941612 hasPrimaryLocation W25449416121 @default.
• W2544941612 hasRelatedWork W103508165 @default.
• W2544941612 hasRelatedWork W1557431515 @default.
• W2544941612 hasRelatedWork W1964442611 @default.
• W2544941612 hasRelatedWork W1988801480 @default.
• W2544941612 hasRelatedWork W2076356674 @default.
• W2544941612 hasRelatedWork W2347335673 @default.
• W2544941612 hasRelatedWork W2347873752 @default.
• W2544941612 hasRelatedWork W2389517225 @default.
• W2544941612 hasRelatedWork W2415241989 @default.
• W2544941612 hasRelatedWork W2421314104 @default.
• W2544941612 hasRelatedWork W2767509507 @default.
• W2544941612 hasRelatedWork W2773854304 @default.
• W2544941612 hasRelatedWork W2796419240 @default.
• W2544941612 hasRelatedWork W2917363934 @default.
• W2544941612 hasRelatedWork W2986158011 @default.
• W2544941612 hasRelatedWork W3007218677 @default.
• W2544941612 hasRelatedWork W3032328944 @default.
• W2544941612 hasRelatedWork W3090846941 @default.
• W2544941612 hasRelatedWork W3160633039 @default.
• W2544941612 hasRelatedWork W1776041243 @default.
• W2544941612 isParatext "false" @default.
• W2544941612 isRetracted "false" @default.
• W2544941612 magId "2544941612" @default.
• W2544941612 workType "article" @default.